Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Jul 31;12(7):1655-1657.
doi: 10.21037/tlcr-23-202. Epub 2023 May 23.

Selpercatinib in patients with RET fusion positive non-small cell lung cancer: updated follow-up of the LIBRETTO-001 phase I/II trial

Thomas E Stinchcombe  1
Affiliations
Editorial

Selpercatinib in patients with RET fusion positive non-small cell lung cancer: updated follow-up of the LIBRETTO-001 phase I/II trial

Thomas E Stinchcombe. Transl Lung Cancer Res. .
No abstract available

Keywords: Targeted therapy; clinical trial; molecular subset.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-202/coif). TES serves as an unpaid editorial board member of Translational Lung Cancer Research from September 2021 to August 2023. TES reports research funding from AstraZeneca, Takeds Seagen Mirati Therapeutics Genentech/Roche (to Institution), and participates consulting or advisory role for Janssen Oncology, Turning Point Therapeutics, Sanofi/Aventis GlaxoSmithKline, Genentech/Roche, Daiichi Sankyo/Astra Zeneca, Takeda, Eisai/H3 Biomedicine, G1 Therapeutic Spectrum Pharmaceuticals. The author has no other conflicts of interest to declare.

Comment on

References

    1. Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2020;383:813-24. 10.1056/NEJMoa2005653 - DOI - PMC - PubMed
    1. Drilon A, Subbiah V, Gautschi O, et al. Selpercatinib in Patients With RET Fusion-Positive Non-Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial. J Clin Oncol 2023;41:385-94. 10.1200/JCO.22.00393 - DOI - PMC - PubMed
    1. McCoach CE, Rolfo C, Drilon A, et al. Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001. J Thorac Oncol 2022;17:768-78. 10.1016/j.jtho.2022.02.004 - DOI - PMC - PubMed
    1. Kalchiem-Dekel O, Falcon CJ, Bestvina CM, et al. Brief Report: Chylothorax and Chylous Ascites During RET Tyrosine Kinase Inhibitor Therapy. J Thorac Oncol 2022;17:1130-6. 10.1016/j.jtho.2022.06.008 - DOI - PMC - PubMed
    1. Gainor JF, Curigliano G, Kim DW, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol 2021;22:959-69. 10.1016/S1470-2045(21)00247-3 - DOI - PubMed